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Neisseria meningitidis is a major cause of child-
hood meningitis and septicemia worldwide, with
an estimated 500,000 cases of invasive meningo-
coccal disease occurring annually and > 50,000
deaths.1 Meningococcal disease is associated with
a high case fatality rate (approximately 10%) 
and survivors can develop permanent sequelae
like deafness, seizures, amputation, and mental
retardation.2
N. meningitidis is classified into 12 serogroups
based on polysaccharide capsule composition.
Serogroups A, B, C, W-135, X and Y are the prin-
cipal pathogenic groups and their distribution dif-
fers between regions. Group A remains unique in
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Background/Purpose: Meningococcal disease, including meningitis and sepsis, usually follows an inva-
sive infection by Neisseria meningitidis, and is a major cause of death and morbidity worldwide. Currently
available meningococcal vaccines that consist of pure capsular polysaccharides (serogroups A, C, W-135
and Y) are generally safe and efficacious in adults and children aged > 2 years. The purpose of this study
was to evaluate the immunogenicity, safety and reactogenicity of a single dose of GlaxoSmithKline
Biologicals’ Mencevax™ ACWY vaccine in healthy Taiwanese subjects aged 2–30 years.
Methods: This open, single center, Phase III study was conducted in Taiwan. A single dose of the
Mencevax™ ACWY vaccine was administered to subjects aged 2–30 years. Immunogenicity and safety of
the vaccine were evaluated after vaccination.
Results: The immunogenicity results obtained 1 month after vaccination with Mencevax™ ACWY vaccine
indicated that the vaccine elicited a good immune response in vaccinees aged 2–30 years. This was both in
terms of functional activity directed against meningococcal polysaccharide (A, C, W-135 and Y) as mea-
sured by serum bactericidal assay (> 93% activity against all serogroups), and specific IgG concentrations
measured by ELISA (> 96% seropositivity to all serogroups).
Conclusion: The tetravalent polysaccharide Mencevax™ ACWY meningococcal vaccine was well tolerated
and immunogenic in subjects aged 2–30 years in Taiwan. [J Formos Med Assoc 2009;108(7):539–547]
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its ability to cause large-scale epidemics, mainly
in Africa but also in Asia. The majority of cases 
in Europe and America are caused by groups B
and C.3,4 By the mid-1990s, serogroup Y ac-
counted for around one-third of all cases in the
United States.5
Meningococcal disease has been identified as
a public health problem by WHO, which supports
development of new vaccines that will help elim-
inate this disease.5 Vaccines that contain purified
capsular polysaccharide antigens of serogroups
A, C, Y and W-135 in various combinations have
been available for > 30 years. Various limitations
such as poor immunogenicity of polysaccharide
vaccines in young children aged < 2 years,6 lack
of induction of immunological memory, and in-
duction of immunological hyporesponsiveness,
mean that polysaccharide vaccines are not opti-
mal for preventing meningococcal disease in early
childhood.7 However, these polysaccharide vac-
cines have been highly effective against all vaccine
serogroups in older children and adults, with re-
ported efficacies of 85–100% for serogroups A and
C, although the protection against serogroup C
appears lower in those aged < 10 years.8–13 In the
absence of conjugate vaccines that have the po-
tential to overcome the limitations mentioned
above, the use of polysaccharide vaccines may be
continued in individuals older than 2 years of age,
although the immune response is more favor-
able in older age groups, and the disease burden
is highest in the youngest of children. It is worth-
while to note that a second peak is observed in
adolescents and young adults, and this is more
marked during epidemics.3
Meningococcal disease in Taiwan is relatively
uncommon with 17–81 cases of clinical disease
reported annually between 1996 and 2002.
Although serogroup B and W-135 meningococci
were the only ones isolated before 2000, emer-
gence of serogroups A, C and Y has been observed
since 2001 in Taiwan.14 In other Asian countries,
such as China, where a predominance of serogroup
A has been observed in the last 50 years (account-
ing for 95% of cases of meningococcal disease),
there have been indications of serogroup A being
replaced by group C between 2003 and 2007.15,16
Disease outbreaks caused by serogroup A have
been reported more recently in Asian countries
such as India17 and the Philippines.18 The emer-
gence of A, C and Y serogroups combined with
the occurrence of small-scale outbreaks in Taiwan,
as well as the high case fatality and substantial
morbidity associated with meningococcal disease,
are a public health concern.14 In these circum-
stances, meningococcal vaccines that are capable
of inducing protective immune responses against
four of these serotypes could play an important
role.
A tetravalent vaccine that contains N. menin-
gitidis serogroups A, C, W-135 and Y (Mencevax™
ACWY; GlaxoSmithKline Biologicals, Rixensart,
Belgium) is indicated for active immunization 
of adults and children aged ≥ 2 years. This study
evaluated the immunogenicity, safety and reacto-
genicity of a single dose of this vaccine adminis-
tered to healthy Taiwanese subjects aged 2–30
years.
Materials and Methods
Subjects and study design
This was an open, single center, phase III study
with one group of subjects aged 2–30 years. The
study was conducted at the National Taiwan
University hospital in Taipei, Taiwan. Subjects
were stratified for analyses into three age groups:
2–5, 6–15, and 16–30 years. Written informed
consent was obtained from the subject or parent
or guardian of the subject, as appropriate. Ethical
approval for the study was obtained from the
Department of Health Taiwan and the Ethics
Research Committee of National Taiwan Univer-
sity Hospital where the study was conducted.
Subjects were required to have completed
previous routine childhood vaccinations. Exclu-
sion criteria were: administration of a vaccine
not prescribed by the study protocol; use of any 
investigational or non-registered drug or vaccine
during the study period; chronic administration
(> 14 days) of immunosuppressants or other
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immunomodulating drugs within 6 months prior
to the vaccine dose; history of allergic disease or
reactions to the vaccine components; previous vac-
cination against meningococcal diseases within
the last 3 years; history of meningococcal disease;
or known exposure to meningococcal disease
since birth.
Vaccine
Mencevax™ ACWY vaccine (GlaxoSmithKline
Biologicals) is a lyophilized vaccine (reconstituted
with saline diluent) and each dose (0.5 mL) con-
tains 50 μg of polysaccharide A (PSA), polysaccha-
ride C (PSC), polysaccharide W-135 (PSW-135),
and polysaccharide Y (PSY). A single dose of the
Mencevax™ ACWY vaccine was administered as 
a deep subcutaneous injection in the left upper
arm region, using a 23-gauge, 1-inch needle.
Serological assays
Two blood samples were drawn during the study:
one prior to the vaccine dose (Pre) and the sec-
ond, 1 month after the vaccine dose (Post). Func-
tional anti-meningococcal serogroup C activity
(SBA-MenC) was determined by a serum bacteri-
cidal test according to the Centers for Disease
Control (CDC) protocol,19 using rabbit comple-
ment. The cut-off of the test was a dilution of
1:8. Titers were expressed as the reciprocal of the
dilution that resulted in 50% inhibition. Serum
bactericidal activity (SBA) titers of ≥ 1:4 (using
human complement)20 and ≥ 1:8 (using rabbit
complement) have been used as a surrogate for
protection.21 For serogroups A, W-135 and Y,
there are no data to demonstrate that any SBA
titer correlates with the protective efficacy of a
vaccine. However, by extrapolation, the protec-
tive serum bactericidal antibody assay using rab-
bit complement (MenC rSBA) titer of ≥ 1:8 has
been assumed to indicate protection.4
Meningococcal polysaccharide C specific IgG
was measured by ELISA, based on the CDC pro-
tocol22 with an assay cut-off of 0.3 μg/mL. For
the present study, an ELISA cut-off of 2 μg/mL was
based on the correlate of protection proposed for
the plain meningococcal A and C polysaccharide
vaccines,23,24 and the same titers established for
A and C have been employed for anti-PSW-135
and anti-PSY antibodies.
Immunogenicity
Immunogenicity of the vaccine was measured in
terms of SBA against N. meningitidis serogroups
A, C, W-135 and Y (SBA-MenA, SBA-MenC, SBA-
MenW-135 and SBA-MenY titers) and in terms of
anti-polysaccharide A, C, W-135 and Y (anti-PSA,
anti-PSC, anti-PSW-135 and anti-PSY) antibody
concentrations, prior to and 1 month after vacci-
nation. For each vaccine antigen, seropositivity
rates (i.e. percentage of subjects with titers/anti-
body concentrations greater than or equal to the
assay cut-off value), geometric mean titer (GMT)/
concentration, and vaccine response were calcu-
lated with their 95% confidence intervals by age
group and total. Vaccine response was defined as
seroconversion with an SBA titer cut-off of 1:8 for
initially seronegative subjects (i.e. SBA titer < 1:8),
and a four-fold increase in SBA titers from pre- to
post-vaccination for subjects seropositive at the
pre-vaccination timepoint.
Reactogenicity
Standardized criteria and grading systems were
used to assess vaccine reactogenicity (Table 1).
Any reaction at the injection site or systemic re-
actions reported by the subjects or their parents/
guardians were recorded using diary cards.
Statistical analyses
All analyses were performed as described in the
protocol using SAS version 8.2 (SAS Institute, Inc.,
Cary, NC, USA). The analysis of immunogenicity
was performed on the per-protocol cohort. SBA
and antibody concentrations against all vaccine
antigens were assessed prior to and 1 month
after vaccination. The analysis for reactogenicity
was performed on all subjects who had received
at least one dose of the study vaccine. The per-
centage of subjects who reported at least one so-
licited or unsolicited symptom(s) was tabulated.
Serious adverse events (SAEs) and withdrawals
due to AEs and SAEs were described in detail.
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Results
A total of 105 subjects were enrolled and vacci-
nated between October and December 2003 at 
a single center at the National Taiwan University
Hospital. Of these, 101 subjects were included in
the per protocol immunogenicity analysis. Three
subjects (all in the 2–5 years age group) received
vaccines (Japanese encephalitis vaccine, polio-
virus vaccine, hepatitis A vaccine) within 30 days
of vaccine administration. One subject in the
16–30 years age group who received chronic me-
dication during the study, which was a protocol-
defined exclusion criterion, had chronic cardiac
disease (mitral valve prolapse) for which chronic
medication was given. All vaccinated subjects
were included in the safety analysis. The demo-
graphic characteristics of the different age groups
are listed in Table 2.
Immunogenicity results
SBA-MenA, SBA-MenC, SBA-MenW-135 and 
SBA-MenY titers
Prior to vaccination, a substantial percentage of
the population had an SBA titer ≥ 1:8 for each
serogroup (99% for MenA, 51% for MenC, 23.2%
for MenW-135, and 75% for MenY). These pre-
existing bactericidal titers ≥1:8 were similar across
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Table 1. Solicited symptoms and assessment of their intensity
Age
Symptom Grade
2–5 yr 6–30 yr
Pain 0 Absent Absent
1 Minor reaction to touch Painful on touch
2 Cried/protested on touch Painful when limb was moved
3 Cried when limb was moved/ Pain that prevented normal 
spontaneously painful activity
Redness/swelling 0 None None
1 > 0 to ≤ 10 mm > 0 to ≤ 20 mm
2 > 10 to ≤ 30 mm > 20 to ≤ 50 mm
3 > 30 mm > 50 mm
Fever 0 < 37.5°C < 37.5°C
1 ≥ 37.5°C to ≤ 38.5°C ≥ 37.5°C to ≤ 38.5°C
2 > 38.5°C to ≤ 39.5°C > 38.5°C to ≤ 39.5°C
3 > 39.5°C > 39.5°C
Table 2. Summary of demographic characteristics by age group
Characteristics Parameters or categories
2–5 yr 6–15 yr 16–30 yr Total
(n = 32) (n = 35) (n = 34) (n = 101)
Age (yr) Mean 3.8 8.8 25.6 12.9
Standard deviation 1.25 2.41 2.51 9.5
Median 4.0 9.0 25.0 9.0
Min–max 2–5 6–15 22–29 2–29
n (%) n (%) n (%) n (%)
Sex Female 16 (50) 14 (40) 28 (82.4) 58 (57.4)
Male 16 (50) 21 (60) 6 (17.6) 43 (42.6)
Race East/Southeast Asian 32 (100) 35 (100) 34 (100) 101 (100)
Min = minimum; Max = maximum.
the three age groups for serogroups A and Y, and
increased from the youngest to the oldest age
groups for serogroups C and W-135. One month
after the vaccine dose, all subjects in the three
age groups achieved SBA-MenA, SBA-MenC and
SBA-MenY titers ≥ 1:8. At least 93.8% of subjects
in all three age groups had achieved SBA-MenW-
135 titers ≥ 1:8 (Figure 1).
There was a marked increase in GMT from pre-
to post-vaccination for all four serogroups; over-
all GMTs achieved from pre- to post-vaccination
were 770.6–3786.7 for SBA-MenA, 21.8–4116.8 for
SBA-MenC, 10.7–1185 for SBA-MenW-135, and
126.5–2390.5 for SBA-MenY. For serogroups A
and Y, and to a lesser extent for serogroups C and
W-135, bactericidal titers tended to be higher in
subjects from the two older age strata (i.e. 6–15
and 16–30 years).
Vaccine response
Overall, the vaccine response was 52.6% for 
SBA-MenA, 99% for SBA-MenC, 90.5% for SBA-
MenW-135, and 71.6% for SBA-MenY, i.e. lower
for the serogroups A and Y, as a higher percent-
age of subjects had pre-existing antibodies against
these two serogroups. With the exception of two
subjects in the 2–5 years age group who did not
seroconvert for SBA-MenW-135, all seronegative
subjects seroconverted after vaccination for each
of the four serogroups. Thus, the seroconversion
rate was 100%, 100%, 99.7% and 100% for
serogroups A, C, W-135 and Y, respectively.
Anti-PSA, anti-PSC, anti-PSW-135, anti-PSY
antibody concentrations
Prior to vaccination, close to half of the subjects
were seropositive for anti-PSA antibodies; this was
less for the other three serogroups (6.1–14.1%
depending on the serogroup). An age-dependent
increase in seropositivity status was observed at
pre-vaccination. Seropositivity rates in the 2–5,
6–15 and 16–30 years age groups were: 31.3%,
45.2% and 90.6% for anti-PSA; 3.2%, 0% and
15.2% for anti-PSC; 3.1%, 5.7% and 15.2% for
anti-PSW-135; and 6.3%, 8.8% and 27.3% for
anti-PSY.
One month after the vaccine dose, all subjects
in all three age groups, independent of sero-
logical status at pre-vaccination, had anti-PSA,
anti-PSC and anti-PSY antibody concentrations
≥ 0.3 μg/mL; 96.9% of subjects had anti-PSW-135
antibody concentrations ≥ 0.3 μg/mL in the 2–5
years age group, and 100% in the other two age
groups. Overall, at least 90.1% of subjects had
anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY
antibody concentrations ≥ 2 μg/mL (Figure 2).
There was a robust increase in anti-PS GMCs
from pre- to post-vaccination in all subjects, with
an increase in GMC from 0.56 to 36.94 μg/mL
for anti-PSA, 0.17 to 48.52 μg/mL for anti-PSC,
0.18 to 12.54 μg/mL for anti-PSW-135, and 0.20
to 21.87 μg/mL for anti PSY. For serogroups A
and W-135, the antibody concentration tended
to be higher in the two older age groups (i.e.
6–15 and 16–30 years).
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Figure 1. Seropositivity rates (≥ 1:8) for serum bactericidal activity (SBA)-MenA, SBA-MenC, SBA-MenW-135 and 
SBA-MenY by age group. Pre = blood sampling before vaccination; Post = blood sampling 1 month after vaccination.
Safety/reactogenicity results
The percentage of subjects reporting any symp-
tom (solicited/unsolicited or local/general) was
39%. The symptom most often reported was pain
at the injection site (31.4%). Fever (axillary tem-
perature ≥37.5°C) was reported by 3.8%. For one
subject in the 2–5 years age group, a rash was 
reported that was considered to be related to vac-
cination by the investigator. None of the subjects
reported any severe symptoms. No SAEs were 
reported during the study. No subject withdrew
from the study because of AEs.
Discussion
In this study in Taiwan, a tetravalent meningo-
coccal vaccine was evaluated in a population 
of children, adolescents, and young adults. The 
incidence of reported solicited local and general
symptoms was similar across the three age groups.
The most commonly reported symptom was pain
at the injection site. Fever was reported by < 5%
of subjects. The results from our study are consis-
tent with other studies of polysaccharide vaccines
in which a low incidence of AEs have been re-
ported in adults and children.9,10,12,25 In previous
studies, polysaccharide meningococcal vaccines
have been generally well-tolerated with mild AEs.
The most frequent reaction reported is pain and
redness at the injection site, which lasts for 1–2
days. The incidence of such local reactions varies,
ranging from 4% to 56%. Transient fever has oc-
curred in up to 5% of vaccinees in some studies
and has occurred more commonly in infants.6
SBA is considered to be a surrogate for pro-
tection against meningococcal disease, and a titer
of 1:8 is considered to provide an estimate of
protection.21,26 In the present study, an immune
response considered to be protective against me-
ningococcal infection was seen in > 93% of vac-
cine recipients, in terms of serum bactericidal
antibody titers ≥ 1:8. With the exception of three
subjects who were seronegative for SBA-MenW-
135 and who did not seroconvert, all other ini-
tially seronegative subjects seroconverted after
vaccination for each of the four serogroups. Sero-
conversion of 100% has been observed in other
studies conducted in children > 3 years old.27
In terms of SBA GMTs, the results in this study
are within the same range as those reported in
the literature,28 and are promising considering
that a single dose of polysaccharide A and C vac-
cine induces antibodies for up to 5–10 years in
older children and adults29 and for ≥ 3 years in
recipients aged > 4 years.30 Relative efficacy (75–
100%) at school age and after, and an acceptably
short persistence of antibodies has been reported
as a property common to polysaccharide vaccines
against groups A, C, Y and W135.23
N. meningitidis is a common inhabitant of the
mucosal membranes of the human nasopharynx,
P.L. Shao, et al
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Figure 2. Proportions of subjects with antibody concentrations > 0.3 μg/mL and 2 μg/mL for anti-PSA, anti-PSC, anti-
PSW-135 and anti-PSY by age group. Pre = blood sampling before vaccination; Post = blood sampling 1 month after 
vaccination. White bars represent a cut-off of 0.3 μg/mL and gray bars represent a cut-off of 2 μg/mL.
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where it usually lies as a harmless commensal. 
In non-epidemic settings, up to 5–10% of a pop-
ulation may be asymptomatic carriers, and infec-
tion may be acquired by person-to-person contact
through aerosol droplets or contacts with res-
piratory secretions from asymptomatic carriers.
Studies conducted in Taiwan have shown that
nasopharyngeal carriage of meningococci in mil-
itary recruits was 2.3%.31 Of note was the high
seropositivity rates in the pre-vaccination blood
samples of study subjects. This suggests that col-
onization or infection with N. meningitidis may
not be uncommon in Taiwan, although it is also
well known that cross-reactive antigens from 
enteric bacteria may induce natural immunity.32
Serological typing performed to determine the
antigenic properties of 127 invasive N. meningitidis
isolates collected in Taiwan between 1995 and
2002 has suggested that serogroup B and W-135
isolates are endemic, and that serogroup A, C,
and Y isolates have been imported, which may
be a reflection of increased international travel.33
In addition, N. meningitidis (1.5%) is among other
causative bacterial organisms that contribute to
the occurrence of meningitis in community-
acquired adult bacterial meningitis.34
The most effective means of preventing and
controlling meningococcal disease is through
vaccination.23 Studies evaluating the framework
for vaccination strategies have suggested that rou-
tine immunization of an adequately large subset
of the population with an effective quadrivalent
vaccine can lead to substantial reductions in dis-
ease. Meningococcal conjugate vaccines have been
developed recently with the aim of extending pro-
tection in young children aged < 2 years and not
protected by the polysaccharide vaccines. Menin-
gococcal conjugate vaccines aim also to induce 
a memory response and longer persistence of
protective antibodies. To date, meningococcal
serogroup C conjugate vaccines are available for
use from 2 months of age, although they are 
not available in Taiwan. A tetravalent conjugate
vaccine is available in North America only.28 In
the absence of conjugate vaccines, tetravalent
meningococcal capsular polysaccharide vaccines
can still be considered for control of meningo-
coccal outbreaks and routine vaccination of indi-
viduals known to be at particularly high risk of
disease (e.g. those in armed forces units, training
camps, or boarding schools, and travelers to epi-
demic areas), and for persons with immunologi-
cal predisposition to meningococcal disease
(such as asplenia and inherited immunological
deficiencies).35
As different approaches to reducing disease
burden of meningococcal disease through vac-
cination are being explored, the present study
supplements available data on combined polysac-
charide vaccines. In conclusion, the immunoge-
nicity results obtained 1 month after vaccination
with Mencevax™ ACWY vaccine indicated that
the vaccine elicited a good immune response in
Taiwanese vaccinees aged 2–30 years. Importantly,
the vaccine was well-tolerated and no SAEs were
reported.
Footnote
Mencevax™ ACWY is a trademark of the
GlaxoSmithKline group of companies.
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